The Darker Side of Psychedelics and Psychedelic-Assisted Therapy

In this course, psychologist and addictions expert Dr. Kevin Alderson, Ph.D., introduces a critical and clinically grounded examination of the darker side of psychedelics and psychedelic-assisted therapy. The course explores limitations in the research base, including expectancy effects, blinding challenges, small sample sizes, inadequate adverse-event tracking, and limited long-term follow-up. Dr. Alderson also examines recreational use, microdosing, psychosis risk, suggestibility, ethical concerns, cultural considerations, and the potential for public enthusiasm to outpace evidence. You are guided to respond thoughtfully when clients disclose psychedelic use, provide balanced psychoeducation, assess risks, and maintain a clear focus on safety, informed consent, and sustained behavioural change.